Blanket Purchase Agreement 36F79719D0170-36C26123A0025
Award Date
2/10/23
Last Date to Order
12/31/27
Federal Agency
Veterans Integrated Service Network 21
Awardee
Progenics Pharmaceuticals Inc.
Ultimate Awardee
Lantheus Holdings, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a Blanket Purchase Agreement to Progenics Pharmaceuticals Inc. for PYLARIFY products and services. The single award BPA, valued at over $1.3 million, was issued on July 15, 2022 against the Pharmaceuticals and Drugs Federal Supply Schedule master contract for the period of July 15, 2022 through June 14, 2024. Performance will take place in New York, New York. The BPA calls authorize...
Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings Inc., was awarded a Blanket Purchase Agreement (BPA) by the U.S. Department of Veterans Affairs (VA) to provide PYLARIFY (piflufolastat F-18), a radiopharmaceutical used for positron emission tomography (PET) imaging of prostate cancer. The BPA, valued at up to $5.5 million, is associated with the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and allows various VA medical facilities to issue task orders for...
The U.S. Department of Veterans Affairs (VA) has awarded Blanket Purchase Agreements (BPAs) totaling over $4.3 million to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the delivery of PYLARIFY (piflufolastat F-18), a radiopharmaceutical used in positron emission tomography (PET) scans to detect prostate cancer. These BPAs, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), allow various VA healthcare facilities across the Veterans...
The Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the provision of PYLARIFY (piflufolastat F-18) injection, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The single-award BPA, valued at $2,634,365.60, was established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and has...
The key products and services being delivered under this Blanket Purchase Agreement (BPA) federal contract Indefinite Delivery Vehicle (IDV) are PYLARIFY (piflufolastat F-18), a radiopharmaceutical drug used for positron emission tomography (PET) imaging of prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. and a subsidiary of Lantheus Holdings, Inc. The contract, valued at up to $1,188,615.44, was awarded by the U.S....
The key products and services being delivered under this federal contract Indefinite Delivery Vehicle (IDV) award are radiopharmaceuticals, specifically F-18 PYLARIFY, a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The prime contractor is Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., a for-profit pharmaceutical company specializing in innovative diagnostic imaging agents. The $5,990,475.20 Indefinite...
This is a $2,616,322.00 Indefinite Delivery Contract (IDC) awarded by the U.S. Department of Veterans Affairs (VA), specifically through Veterans Integrated Service Network (VISN) 9, to Pharmalogic Holdings Corp. (doing business as Pharmalogic Puerto Rico). The contract is for the delivery of PYLARIFY F-18 piflufolastat, a radiopharmaceutical used for prostate cancer imaging, to support the VA's nuclear medicine services and imaging programs for veterans. The contract has a 5-year performance...
The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 9, has awarded a single-award Blanket Purchase Agreement (BPA) to Advanced Accelerator Applications USA Inc., a foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The BPA has a ceiling value of $49,212,356.34 and a period of performance from December 2024 to November 2029, with five ordering periods. The BPA is for the manufacture and delivery of Pluvicto (lutetium Lu 177...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a Blanket Purchase Agreement (BPA) contract to Telix Pharmaceuticals US Inc. for the provision of various radiopharmaceuticals. The single-award BPA has a ceiling value of $4,498,000.00 and a period of performance from October 1, 2023 through September 30, 2028. Under this BPA, the VA VHA has issued a $910,000.00 firm fixed price BPA Call Order to Telix Pharmaceuticals US Inc. for the base period from...
The U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract to Telix Pharmaceuticals US Inc., a global biopharmaceutical company, to provide radiopharmaceutical products for nuclear medicine and medical imaging services. The $225,000 multiple-award contract has an ultimate completion date of August 2027 and falls under FSS 65 I B for drugs, pharmaceuticals, and related products. Under this FSS contract, the VA has issued several firm fixed-price delivery...